TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Instagram Outage Disrupts Thousands of U.S. Users 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
 - EconoTimes)
NEW YORK, Dec. 20, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into NovoCure Limited (NVCR) (“NovoCure”). If you are a NovoCure shareholder, you are encouraged to contact Scott+Scott at (800) 404-7770, email [email protected] or go to: http://www.scott-scott.com/cases/investigations/securities-fraud-litigation-3079-novocure-limited.html.
NovoCure develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (“TTFields”). NovoCure markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.
On July 28, 2016, NovoCure announced that its new Optune prescriptions fell to 657 in 2Q from 755 in 1Q. Asaf Danziger, Chief Executive Officer of Novocure stated that “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
On this news, NovoCure’s stock fell from a July 27, 2016 price of $11.44 to a July 28, 2016 price of $8.09, a one-day decline of over 29%.
If you are a NovoCure shareholder and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Michael Burnett at (800) 404-7770, or at [email protected].
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott have significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]
